1. Alpha Calcitonin Gene-related Peptide, Neuropeptide Y, and Substance P as Biomarkers for Diagnosis and Disease Activity and Severity in Multiple Sclerosis.
- Author
-
Al-Keilani MS, Almomani BA, Jaradat SA, Al-Sawalha NA, and Qawasmeh MA
- Subjects
- Humans, Biomarkers, Calcitonin Gene-Related Peptide, Neuropeptide Y, Substance P, Multiple Sclerosis diagnosis, Multiple Sclerosis, Relapsing-Remitting diagnosis
- Abstract
Background: Alpha calcitonin gene-related peptide (aCGRP), neuropeptide Y (NPY), and substance P (SP) are neuropeptides that have emerged recently as potent immunomodulatory factors with potential as novel biomarkers and therapeutic targets in multiple sclerosis (MS)., Objective: The study aimed to detect serum levels of aCGRP, NPY, and SP in MS patients versus healthy controls and their association with disease activity and severity., Methods: Serum levels were measured in MS patients and age and sex-matched healthy controls using ELISA., Results: We included 67 MS patients: 61 relapsing-remitting MS (RR-MS) and 6 progressive MS (PR-MS), and 67 healthy controls. Serum NPY level was found to be lower in MS patients than in healthy controls ( p < 0.001). Serum aCGRP level was higher in PR-MS compared to RR-MS ( p = 0.007) and healthy controls ( p = 0.001), and it positively correlated with EDSS (r = 0.270, p = 0.028). Serum NPY level was significantly higher in RR-MS and PR-MS than in healthy controls ( p < 0.001 and p = 0.001, respectively), and it was lower in patients with mild or moderate/severe disease than in healthy controls ( p < 0.001). Significant inverse correlations were found between SP level and MS disease duration (r = -0.279, p = 0.022) and duration of current DMT (r = -0.315, p = 0.042)., Conclusion: Lower serum levels of NPY were revealed in MS patients compared to healthy controls. Since serum levels of aCGRP are significantly associated with disease activity and severity, it is a potential disease progression marker., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2024
- Full Text
- View/download PDF